tbuckley/cabot-search huggingface dataset:
Venous Thromboembolism (VTE) in Patients with Hodgkin Lymphoma: Retrospective Evaluation of Throly and Khorana Risk Scores
Authors: Giovanni Manfredi Assanto, Martina Salvatori, Sara Pontecorvo, Natalia Cenfra, Gianna Maria D'elia, Giorgia Annechini, Maurizio Martelli, Alessandro Pulsoni, Ilaria Del Giudice, Antonio Chistolini
Journal: Blood (2022)
The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function
Authors: Parmeshwar N. Amatya, Reyka G. Jayasinghe, Alun J. Carter, Matthew L. Cooper, Jonathan A. Pachter, John F. DiPersio, Julie K. Ritchey
Journal: Blood (2022)
Combination of DLI to Blinatumomab in Post- Transplant Molecular Relapse of Pediatric High- Risk ALL
Authors: Fabiana Cacace, Selenia Vitiello, Franceso Muriano, Daniela D'Angelo, Valeria Caprioli, Maria Rosaria D'Amico, Giuseppina De Simone, Rosanna Parasole, Francesco Paolo Paolo Tambaro
Journal: Blood (2022)
African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction
Authors: Laura Sun, Kathryn T. Maples, Kevin H. Hall, Yuan Liu, Yichun Cao, Nisha S. Joseph, Craig C Hofmeister, Jonathan L. Kaufman, Madhav Dhodapkar, Ajay K. Nooka, Sagar Lonial, R Donald Harvey
Journal: Blood (2022)
Real-World Data on the Use of Luspatercept in Greek Patients with Transfusion Dependent Thalassemia
Authors: Polyxeni Delaporta, Alexandra Kourakli, Sophia Delicou, Michael D. Diamantidis, Chrysoula Kalkana, Efthymia Vlachaki, Eftychios Eftychiadis, Ioannis Lafiatis, Despoina Pantelidou, Argiris Symeonidis, Vasileios Lazaris, Aikaterini Xydaki, Achilles Manafas, Loukia Evliati, Filippos Klonizakis, Ioanna Manika, Despoina Papadopoulou, Marianna Chatzieleftheriou, Konstantina Toutoudaki, Dimitra Kyriakopoulou, Antonis Kattamis
Journal: Blood (2022)
OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators
Authors: Fredrik Schjesvold, Heinz Ludwig, María-Victoria Mateos, Haifaa Abdulhaq, Stefan Norin, Marcus Thuresson, Nicolaas A. Bakker, Paul G. Richardson, Pieter Sonneveld
Journal: Blood (2022)
Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission
Authors: Adam D Cohen, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Oksana De Mesa, Elizabeth Kane, Charles Nichols, Beatrice Razzo, Edward A. Stadtmauer
Journal: Blood (2022)
Long-Term Real-World Outcomes of Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide and All Trans Retinoic Acid without Chemotherapy
Authors: Charanpreet Singh, Uday Yanamandra, Parathan Karunakaran, Nishant Jindal, Saloni Rani Kumar, Neha Saini, Aditya Jandial, Arihant Jain, Chandan Das, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Shano Naseem, Reena Das, Neelam Varma, Subhash Varma, Pankaj Malhotra
Journal: Blood (2022)
Clinical Characteristics and Outcomes of Newly Diagnosed Patients with HIV-Associated Aggressive B-Cell NHL in China
Authors: Chaoyu Wang, Jun Liu, Bingling Guo, Renzhi Hu, Tingting Liu, Jing Wu, Yao Ding, Chongling Hu, Shunsi Liang, Chunyan Xiao, Dehong Huang, Tao Yang, Wenjun Zhang, Zailin Yang, Jieping Li, Yingyu Nan, Qiying Li, Ying Xiang, Yao Liu
Journal: Blood (2022)
Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma
Authors: Mirco Friedrich, Niklas Kehl, Simon Steiger, Tim Robin Wagner, Katharina Lindner, Michael Kilian, Julius Michel, Sebastian Uhrig, Raphael Lutz, Nina Prokoph, Alexandra M Poos, Lukas John, Lilli Sophie Sester, Niels Weinhold, Stefan Fröhling, Edward W Green, Lukas Bunse, Paola Neri, Nizar Jacques Bahlis, Karsten Rippe, Stefan Eichmüller, Carsten Müller-Tidow, Hartmut Goldschmidt, Michael Platten, Marc S Raab
Journal: Blood (2022)
Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
Authors: Mohammad S Ebraheem, Eli Muchtar, Shaji K Kumar, Angela Dispenzieri, Francis K. Buadi, David Dingli, Joselle Cook, Martha Q. Lacy, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Rahma M Warsame, Taxiarchis Kourelis, Moritz Binder, Ronald Go, Amie Fonder, Yi L. Hwa, Miriam A. Hobbs, Wilson I. Gonsalves, S. Vincent Rajkumar, Robert A. Kyle, Morie A Gertz
Journal: Blood (2022)
The <i>in Vitro</i> and <i>In Vivo</i> Effects of DPP-4 Inhibition with Sitagliptin, Alone and in Combination with Bortezomib, on T Cell Activation: Rationale for GvHD Prevention
Authors: Shuhong Zhang, Xingkui Xue, Maggie Granatir, George E. Sandusky, Sheng Liu, Jun Wan, Xiaoling Xuei, Yunlong Liu, Anthony L. Sinn, Karen E. Pollok, Sherif S Farag
Journal: Blood (2022)
Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background
Authors: Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine E Birdwell, Kaberi Das, John A. Davis, Noor Alhamadani, Kevin Philip, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Blood (2022)
CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms
Authors: Akinori Yoda, Daisuke Morishita, Yotaro Ochi, Akio Mizutani, Takuto Mori, June Takeda, Hirokazu Tozaki, Yoshihiko Satoh, Yasuhito Nannya, Hideki Makishima, Hiroshi Miyake, Seishi Ogawa
Journal: Blood (2022)
Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia
Authors: Simon Renders, Alexander Waclawiczek, Aino-Maija Leppä, Cecilia Reyneri, Barbara Betz, Karolin Stumpf, Maike Janssen, Julia M. Unglaub, Elisa Donato, Rabia Shahswar, Simon Raffel, Michael Heuser, Richard F. Schlenk, Michael Hundemer, Tim Sauer, Carsten Müller-Tidow, Andreas Trumpp
Journal: Blood (2022)
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
Authors: Matthew G Cyr, Maissa Mhibik, Junpeng Qi, Haiyong Peng, Jing Chang, Erika M Gaglione, David Eik, John Herrick, Thomas Venables, Scott J Novick, Valentine V Courouble, Patrick R Griffin, Adrian Wiestner, Christoph Rader
Journal: Journal for ImmunoTherapy of Cancer (2022)

Despite numerous therapeutic options, safe and curative therapy is unavailable for most patients with chronic lymphocytic leukemia (CLL). A drawback of current therapies such as the anti-CD20 monoclonal antibody (mAb) rituximab is the elimination of all healthy B cells, resulting in impaired humoral immunity. We previously reported the identification of a patient-derived, CLL-binding mAb, JML-1, and identified sialic acid-binding immunoglobulin-like lectin-6 (Siglec-6) as the target of JML-1. Although little is known about Siglec-6, it appears to be an attractive target for cancer immunotherapy due to its absence on most healthy cells and tissues. We used a target-specific approach to mine for additional patient-derived anti-Siglec-6 mAbs. To assess the therapeutic utility of targeting Siglec-6 in the context of CLL, T cell-recruiting bispecific antibodies (T-biAbs) that bind to Siglec-6 and CD3 were engineered into single-chain variable fragment-Fc and dual-affinity retargeting (DART)-Fc constructs. T-biAbs were evaluated for their activity in vitro, ex vivo, and in vivo. We discovered the anti-Siglec-6 mAbs RC-1 and RC-2, which bind with higher affinity than JML-1 yet maintain similar specificity. Both JML-1 and RC-1 T-biAbs were effective at activating T cells and killing Siglec-6+ target cells. The RC-1 clone in the DART-Fc format was the most potent T-biAb tested and was the only anti-Siglec-6 T-biAb that eliminated Siglec-6+ primary CLL cells via autologous T cells at pathological T-to-CLL cell ratios. Tested at healthy T-to-B cell ratios, it also eliminated a Siglec-6+ fraction of primary B cells from healthy donors. The subpicomolar potency of the DART-Fc format was attributed to the reduction in the length and flexibility of the cytolytic synapse. Furthermore, the RC-1 T-biAb was effective at clearing MEC1 CLL cells in vivo and demonstrated a circulatory half-life of over 7 days. Siglec-6-targeting T-biAbs are highly potent and specific for eliminating Siglec-6+ leukemic and healthy B cells while sparing Siglec-6- healthy B cells, suggesting a unique treatment strategy for CLL with diminished suppression of humoral immunity. Our data corroborate reports that T-biAb efficacy is dependent on synapse geometry and reveal that synapse architecture can be tuned via antibody engineering. Our fully human anti-Siglec-6 antibodies and T-biAbs have potential for cancer immunotherapy. NCT00923507.
Emotion-related impulsivity and risky decision-making: A systematic review and meta-regression
Authors: Matthew V. Elliott, Sheri L. Johnson, Jennifer G. Pearlstein, Daniela E. Muñoz Lopez, Hanna Keren
Journal: Clinical Psychology Review (2022)

Emotion-related impulsivity, the trait-like tendency toward regrettable behavior during states of high emotion, is a robust predictor of internalizing and externalizing psychopathology. Despite substantial evidence that emotion-related impulsivity is important transdiagnostically, relatively little is known about its cognitive correlates. This systematic review and meta-regression investigates one such candidate, risky decision-making. We analyzed 195 effect sizes from 51 studies of 14,957 total participants, including 105 newly calculated effect sizes that were not reported in the original publications. The meta-regression demonstrated evidence for a small, positive relationship of emotion-related impulsivity with behavioral indices of risky decision-making (ß = 0.086). Effects generalized across sample age, gender, Positive versus Negative Urgency, and clinical versus nonclinical samples. The average effect size varied by task type, with stronger effects for the Iowa Gambling Task and Delay Discounting Task. Experimental arousal manipulation was nearly a significant moderator, with stress and pharmacological manipulations yielding significant effect sizes. Analyses indicated that publication bias did not skew the current findings. Notwithstanding limitations, the data suggest that risky decision-making is a cognitive domain that relates to emotion-related impulsivity. We conclude with recommendations regarding the specific types of tasks and arousal inductions that will best capture emotion-related impulsivity in future experimental research.
STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation
Authors: Etienne Masle-Farquhar, Katherine J.L. Jackson, Timothy J. Peters, Ghamdan Al-Eryani, Mandeep Singh, Kathryn J. Payne, Geetha Rao, Danielle T. Avery, Gabrielle Apps, Jennifer Kingham, Christopher J. Jara, Ksenia Skvortsova, Alexander Swarbrick, Cindy S. Ma, Daniel Suan, Gulbu Uzel, Ignatius Chua, Jennifer W. Leiding, Kaarina Heiskanen, Kahn Preece, Leena Kainulainen, Michael O’Sullivan, Megan A. Cooper, Mikko R.J. Seppänen, Satu Mustjoki, Shannon Brothers, Tiphanie P. Vogel, Robert Brink, Stuart G. Tangye, Joanne H. Reed, Christopher C. Goodnow
Journal: Immunity (2022)

The association between cancer and autoimmune disease is unexplained, exemplified by T cell large granular lymphocytic leukemia (T-LGL) where gain-of-function (GOF) somatic STAT3 mutations correlate with co-existing autoimmunity. To investigate whether these mutations are the cause or consequence of CD8+ T cell clonal expansions and autoimmunity, we analyzed patients and mice with germline STAT3 GOF mutations. STAT3 GOF mutations drove the accumulation of effector CD8+ T cell clones highly expressing NKG2D, the receptor for stress-induced MHC-class-I-related molecules. This subset also expressed genes for granzymes, perforin, interferon-γ, and Ccl5/Rantes and required NKG2D and the IL-15/IL-2 receptor IL2RB for maximal accumulation. Leukocyte-restricted STAT3 GOF was sufficient and CD8+ T cells were essential for lethal pathology in mice. These results demonstrate that STAT3 GOF mutations cause effector CD8+ T cell oligoclonal accumulation and that these rogue cells contribute to autoimmune pathology, supporting the hypothesis that somatic mutations in leukemia/lymphoma driver genes contribute to autoimmune disease.
The Arabidopsis TIR-NBS-LRR protein CSA1 guards BAK1-BIR3 homeostasis and mediates convergence of pattern- and effector-induced immune responses
Authors: Sarina Schulze, Liping Yu, Chenlei Hua, Lisha Zhang, Dagmar Kolb, Hannah Weber, Alexandra Ehinger, Svenja C. Saile, Mark Stahl, Mirita Franz-Wachtel, Lei Li, Farid El Kasmi, Thorsten Nürnberger, Volkan Cevik, Birgit Kemmerling
Journal: Cell Host & Microbe (2022)
NICE’s new methods: putting innovation first, but at what cost?
Authors: Victoria Charlton, James Lomas, Polly Mitchell
Journal: BMJ (2022)

Traditionally the gatekeeper to the NHS, NICE has increasingly reoriented its role towards facilitating access to innovative technologies. This change has clear benefits for some patients, but the costs shouldered by others risk going unacknowledged, say <b>Victoria Charlton and colleagues</b>
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study
Authors: Bin Xu, San-Yuan Dong, Xue-Li Bai, Tian-Qiang Song, Bo-Heng Zhang, Le-Du Zhou, Yong-Jun Chen, Zhi-Ming Zeng, Kui Wang, Hai-Tao Zhao, Na Lu, Wei Zhang, Xu-Bin Li, Su-Su Zheng, Guo Long, Yu-Chen Yang, Hua-Sheng Huang, Lan-Qing Huang, Yun-Chao Wang, Fei Liang, Xiao-Dong Zhu, Cheng Huang, Ying-Hao Shen, Jian Zhou, Meng-Su Zeng, Jia Fan, Sheng-Xiang Rao, Hui-Chuan Sun
Journal: Liver Cancer (2022)

Lenvatinib plus an anti-PD-1 antibody has shown promising antitumor effects in patients with advanced hepatocellular carcinoma (HCC), but with clinical benefit limited to a subset of patients. We developed and validated a radiomic-based model to predict objective response to this combination therapy in advanced HCC patients.
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
Authors: Masatoshi Kudo, Richard S. Finn, Peter R. Galle, Andrew X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni
Journal: Liver Cancer (2022)

The phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease.Patients with systemic treatment-naive unresectable HCC and Child-Pugh class A liver function were randomized 2:1 to receive 1,200 mg of atezolizumab plus 15 mg/kg of bevacizumab or 400 mg of sorafenib. Co-primary endpoints were overall survival (OS) and progression-free survival (PFS) per independent review facility (IRF)-assessed Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in the BCLC stage B subgroup. Patients in this analysis had BCLC stage B disease at baseline per electronic case report form. Secondary efficacy endpoints included the objective response rate (ORR) and change in the sum of longest diameters (SLD) of target lesions from baseline per IRF RECIST 1.1 and modified RECIST (mRECIST) for HCC.Of 501 enrolled patients, 74 (15%) had BCLC stage B disease at baseline (atezolizumab + bevacizumab, n = 49; sorafenib, n = 24). For this group, median follow-up was 19.7 months. A trend toward improved OS and PFS per IRF RECIST 1.1 was observed with atezolizumab + bevacizumab versus sorafenib (OS: hazard ratio [HR]: 0.63; 95% confidence interval [CI]: 0.29, 1.34; PFS: HR: 0.64; 95% CI: 0.36, 1.12). ORRs per IRF RECIST 1.1 and HCC mRECIST were 43% and 50% with atezolizumab + bevacizumab and 26% and 30% with sorafenib, respectively. Percentage change in SLD of target lesions from baseline per IRF RECIST 1.1 and HCC mRECIST showed durable responses with atezolizumab + bevacizumab treatment. Safety data were consistent with known profiles of atezolizumab and bevacizumab, as seen in the overall study population.Efficacy benefits were observed with atezolizumab + bevacizumab in patients with baseline BCLC stage B disease, consistent with the intention-to-treat population.
Retracted papers originating from paper mills: cross sectional study
Authors: Cristina Candal-Pedreira, Joseph S Ross, Alberto Ruano-Ravina, David S Egilman, Esteve Fernández, Mónica Pérez-Ríos
Journal: BMJ (2022)

To describe retracted papers originating from paper mills, including their characteristics, visibility, and impact over time, and the journals in which they were published. Cross sectional study. The Retraction Watch database was used for identification of retracted papers from paper mills, Web of Science was used for the total number of published papers, and data from Journal Citation Reports were collected to show characteristics of journals. All paper mill papers retracted from 1 January 2004 to 26 June 2022 were included in the study. Papers bearing an expression of concern were excluded. Descriptive statistics were used to characterise the sample and analyse the trend of retracted paper mill papers over time, and to analyse their impact and visibility by reference to the number of citations received. 1182 retracted paper mill papers were identified. The publication of the first paper mill paper was in 2004 and the first retraction was in 2016; by 2021, paper mill retractions accounted for 772 (21.8%) of the 3544 total retractions. Overall, retracted paper mill papers were mostly published in journals of the second highest Journal Citation Reports quartile for impact factor (n=529 (44.8%)) and listed four to six authors (n=602 (50.9%)). Of the 1182 papers, almost all listed authors of 1143 (96.8%) paper mill retractions came from Chinese institutions and 909 (76.9%) listed a hospital as a primary affiliation. 15 journals accounted for 812 (68.7%) of 1182 paper mill retractions, with one journal accounting for 166 (14.0%). Nearly all (n=1083, 93.8%) paper mill retractions had received at least one citation since publication, with a median of 11 (interquartile range 5-22) citations received. Papers retracted originating from paper mills are increasing in frequency, posing a problem for the research community. Retracted paper mill papers most commonly originated from China and were published in a small number of journals. Nevertheless, detected paper mill papers might be substantially different from those that are not detected. New mechanisms are needed to identify and avoid this relatively new type of misconduct.
Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects alterations in myeloid differentiation and the influence of inflammatory cytokines
Authors: Gerard Godoy-Tena, Anis Barmada, Octavio Morante-Palacios, Carlos de la Calle-Fabregat, Ricardo Martins-Ferreira, Anna G. Ferreté-Bonastre, Laura Ciudad, Adolfo Ruiz-Sanmartín, Mónica Martínez-Gallo, Ricard Ferrer, Juan Carlos Ruiz-Rodriguez, Javier Rodríguez-Ubreva, Roser Vento-Tormo, Esteban Ballestar
Journal: Genome Medicine (2022)

COVID-19 manifests with a wide spectrum of clinical phenotypes, ranging from asymptomatic and mild to severe and critical. Severe and critical COVID-19 patients are characterized by marked changes in the myeloid compartment, especially monocytes. However, little is known about the epigenetic alterations that occur in these cells during hyperinflammatory responses in severe COVID-19 patients. In this study, we obtained the DNA methylome and transcriptome of peripheral blood monocytes from severe COVID-19 patients. DNA samples extracted from CD14 + CD15- monocytes of 48 severe COVID-19 patients and 11 healthy controls were hybridized on MethylationEPIC BeadChip arrays. In parallel, single-cell transcriptomics of 10 severe COVID-19 patients were generated. CellPhoneDB was used to infer changes in the crosstalk between monocytes and other immune cell types. We observed DNA methylation changes in CpG sites associated with interferon-related genes and genes associated with antigen presentation, concordant with gene expression changes. These changes significantly overlapped with those occurring in bacterial sepsis, although specific DNA methylation alterations in genes specific to viral infection were also identified. We also found these alterations to comprise some of the DNA methylation changes occurring during myeloid differentiation and under the influence of inflammatory cytokines. A progression of DNA methylation alterations in relation to the Sequential Organ Failure Assessment (SOFA) score was found to be related to interferon-related genes and T-helper 1 cell cytokine production. CellPhoneDB analysis of the single-cell transcriptomes of other immune cell types suggested the existence of altered crosstalk between monocytes and other cell types like NK cells and regulatory T cells. Our findings show the occurrence of an epigenetic and transcriptional reprogramming of peripheral blood monocytes, which could be associated with the release of aberrant immature monocytes, increased systemic levels of pro-inflammatory cytokines, and changes in immune cell crosstalk in these patients.
Nanostructured‐Based Optical Readouts Interfaced with Machine Learning for Identification of Extracellular Vesicles
Authors: Carolina del Real Mata, Olivia Jeanne, Mahsa Jalali, Yao Lu, Sara Mahshid
Journal: Advanced Healthcare Materials (2022)

Extracellular vesicles (EVs) are shed from cancer cells into body fluids, enclosing molecular information about the underlying disease with the potential for being the target cancer biomarker in emerging diagnosis approaches such as liquid biopsy. Still, the study of EVs presents major challenges due to their heterogeneity, complexity, and scarcity. Recently, liquid biopsy platforms have allowed the study of tumor-derived materials, holding great promise for early-stage diagnosis and monitoring of cancer when interfaced with novel adaptations of optical readouts and advanced machine learning analysis. Here, recent advances in labeled and label-free optical techniques such as fluorescence, plasmonic, and chromogenic-based systems interfaced with nanostructured sensors like nanoparticles, nanoholes, and nanowires, and diverse machine learning analyses are reviewed. The adaptability of the different optical methods discussed is compared and insights are provided into prospective avenues for the translation of the technological approaches for cancer diagnosis. It is discussed that the inherent augmented properties of nanostructures enhance the sensitivity of the detection of EVs. It is concluded by reviewing recent integrations of nanostructured-based optical readouts with diverse machine learning models as novel analysis ventures that can potentially increase the capability of the methods to the point of translation into diagnostic applications.